Industry News

FDA Approves Novocure’s Optune Pax for the Treatment of Locally Advanced Pancreatic Cancer

On February 11, the FDA approved Optune Pax® for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel.

For more information, read the Novocure press release.

Posted on 2/13/2026


1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
scosonline.com
Email Us